Join us at ISPOR Europe 2024 in Barcelona!

Find us at booth #600

Drop us an email to book a meeting with us.

Our research

Insights from NICE Early Value Assessment for Digital Health Technologies
 
Monday, 18 November, 4:00-7:00 PM
  • A targeted literature review that aims to evaluate NICE’s early value assessment (EVA) process and explores both the potential early impact of digital health technologies on patient care and clinical practice and early stakeholder involvement in facilitating innovation.
  • Key themes across all included EVAs were examined and discussed.

 

 Large Language Models for Outcomes Research
 
Monday, 18 November, 4:00-7:00 PM
  • A targeted literature review examining the application of large language models for health outcomes research. Use cases, recommendations for implementation and future research, and barriers to implementation are summarised.
  • Future research examining approaches to manually validate automated actions, for example using sampling, could help mitigate variations in LLM performance and improve efficiency gains while maintaining research quality. 

Modelling Approaches for Digital Health Technology in NICE's Early Value Assessment
 
Tuesday, 19 November, 10:30 AM-1:30 PM
  • A targeted literature review of early value assessments (EVA) conducted by NICE to appraise digital health technologies. EVAs often face evidence constraints, therefore requiring decisions on how to robustly undertake economic analysis.
  • This research aims to investigate the model structures and approaches used to evaluate the cost-effectiveness of the appraised technologies despite identified evidence gaps. 
The Role of RWE in NICE Submissions for Rare Diseases
 
Tuesday, 19 November, 10:30 AM-1:30 PM
  • The Highly specialised technologies (HST) process by NICE evaluates treatments for rare diseases, where real-world evidence (RWE) is crucial due to limited RCT feasibility.
  • A review of 10 HST submissions (June 2022–May 2024) found RWE used in 9/10 cases to support findings. Though generally accepted, concerns over RWE quality and uncertainty were noted, with additional data collection recommended in 5 cases. 
Large Language Models for Health Economics and HTA Submissions
 
Tuesday, 19 November, 10:30 AM-1:30 PM
  • A targeted literature review examining the application of large language models for health economics research as well as understanding health technology assessment body decision precedent. Research recommendations and barriers to implementation identified by the studies are discussed.
  • Future research should continue to explore the feasibility of integrating LLMs into common HE tasks and develop effective workflows for validating model responses. 
Burden of Disease in Chronic Hand Eczema Patients
 
Tuesday, 19 November, 10:30 AM-1:30 PM
 
  • Chronic hand eczema (CHE) is an inflammatory skin disease that affects the hands and wrists, with symptoms of itch and pain.
  • The burden of CHE was assessed in two systematic literature reviews of healthcare resource use (42 studies) and health-related quality of life (48 studies).
  • Overall, the evidence indicates a significant burden of CHE, which increases with disease severity. 

 

 

The poster's PDF is available on demand.
 
 
Considerations for Modelling in Crowded Treatment Landscapes
 
Tuesday, 19 November, 4:00-7:00 PM
  • This poster examines the unique considerations of health economic modelling in disease areas with multiple available treatments, drawing on insights from recent health technology appraisals in the UK, Canada, Australia, and the US across three disease areas.
  • Building on previous approaches and feedback from HTA bodies, the poster provides recommendations and guidance for optimising model development in crowded landscapes. 
A Simulation Study Assessing a Stopping Rule to Reduce Screening Burden
 
Tuesday, 19 November, 4:00-7:00 PM
  • A simulation study demonstrating a substantial reduction in total records screened during title and abstract screening is possible with a stopping rule. 
  • The rule relies on an initial set of randomly sampled records to certify that a desired percentage of relevant records have been discovered during prioritised screening.
  • The appropriateness of implementing the rule for different review types is discussed. 
How to Improve Credibility through All Phases of Model Development
 
Wednesday, 20 November, 9:00-11:30 AM
  • A targeted literature review which explored the processes involved in validating a health economic model. The 21 unique approaches identified included model tools and conceptual frameworks aimed at developers, users, and external decision-makers.
  • The evidence was synthesised to highlight key methodologies across five key stages of model development: conceptualisation, development, finalisation, reporting, and post-completion. 
 
Unblocking Pricing Power with Threshold Analysis
 
 
Wednesday, 20 November, 9:00-11:30 AM
  • This study explores the use of threshold analyses in early economic models to inform pricing strategies for new treatments.
  • By focusing on the maximum achievable, the analysis demonstrates how pricing can be adjusted based on varying effectiveness assumptions, helping manufacturers optimise strategic decisions.


Our team at ISPOR Europe 2024

ISPOR EU 24 LinkedIn Posts (8)
ISPOR EU 24 LinkedIn Posts (5)-1
ISPOR EU 24 LinkedIn Posts (9)